Clinical Efficacy of Modified Sanxiaoyin in Treatment of Mild or Moderate COVID-19 Patients:Based on Retrospective Analysis.

Objective: To retrospectively analyze the clinical data of 52 patients with coronavirus disease-2019 COVID-19 and explore the clinical efficacy of modified Sanxiaoyin on mild/moderate COVID-19 patients. Method(s): The propensity score matching method was used to collect the clinical data of mild or moderate COVID-19 patients enrolled in the designated hospital of the Second Hospital of Jingzhou from December 2019 to May 2020. A total of 26 eligible patients who were treated with modified Sanxiaoyin were included in the observation group,and the 26 patients treated with conventional method were the regarded as the control. The disappearance of clinical symptoms,disappearance time of main symptoms,efficacy on traditional Chinese medicineTCMsymptoms,hospitalization duration,laboratory test indicators,and CT imaging changes in the two groups were compared. Result(s): The general data in the two groups were insignificantly different and thus they were comparable. After 7 days of treatment,the disappearance rate of fever,cough, fatigue,dry throat,anorexia,poor mental state,and poor sleep quality in the observation group was higher than that in the control groupP<0.05,and the difference in the disappearance rate of expectoration and chest distress was insignificant. For the cases with the disappearance of symptoms,the main symptomsfever, cough,fatigue,dry throat,anorexia,chest distressdisappeared earlier in the observation group than in the control groupP<0.01. After 7 days of treatment,the scores of the TCM symptom scale of both groups decreasedP<0.01,and the decrease of the observation group was larger that of the control groupP<0.01. All patients in the two groups were cured and discharged. The average hospitalization duration in the observation group12.79+/-2.68dwas shorter than that in the control group15.27+/-3.11dP<0.01. The effective rate in the observation group92.31%,24/26was higher than that in the control group76.92%,20/26. After 7 days of treatment,the lymphocyteLYMcount increasedP<0.05,and white blood cellWBCcount and neutrophilNEUTcount decreased insignificantly in the two groups. Moreover,levels of C-reactive protein CRP,erythrocyte sedimentation rateESR,and procalcitoninPCTreduced in the two groups after treatmentP<0.01and the reduction in the observation group was larger than that in the control group P<0.01. Through 7 days of treatment,the total effective rate on pulmonary shadow in the observation group 90.00%,18/20was higher than that in the control group77.27%,17/22P>0.05and the improvement of lung shadow in the observation group was better than that in the control groupP<0.01. Conclusion(s):Modified Sanxiaoyin can significantly alleviate fever,cough,fatigue,anorexia,chest distress,poor sleep quality,and other symptoms of patients with mild or moderate COVID-19,improve biochemical indicators,and promote the recovery of lung function. This paper provides clinical evidence for the application of modified Sanxiaoyin in the treatment of mild or moderate COVID-19.Copyright © 2022, China Academy of Chinese Medical Sciences Institute of Chinese Materia Medica. All rights reserved.

Time series analysis of the number of tuberculosis cases in tangshan area

Objective The time series analysis model was used to predict and warn the number of tuberculosis (TB) cases in Tangshan area in different time, which provided a reference for scientific prevention and control of TB epidemic in this area. Methods The number of monthly TB cases in Tangshan from January 2005 to December 2021 was collected, and the seasonal autoregressive integrated moving average (SARIMA) model was used to predict the number of TB cases in 2022. Meanwhile, the difference between the predicted number of TB cases and the actual observed number of TB cases in the area was explored during the period of COVID-19 in 2020 by this model and rank test. Results From January 2005 to December 2021, the ARIMA (1, 1, 0) (1, 1, 2)s model was fitted well with the actual observed number of TB cases (AR =-0. 530, ARs =-0.967, MAs = 0. 861, P0. 05;Stationary R2 = 0. 558, R2 = 0. 634, BIC = 7. 887;Ljung-Box Q = 25. 605, P 0. 05), with peaks TB incidence in March, April, and December every year, and the predicted number of TB cases in 2020 was 1 800. From 2005 to 2019, ARIMA (1, 1, 0) (0, 1, 2)s model was fitted well with the actual number of cases (AR =-0. 544, ARs =-0. 840, MAs = 0. 697, P 0. 05;Stationary R2 = 0. 582, R2 = 0. 621, BIC = 7. 939;Ljung-Box Q = 24. 211, P 0. 05), with peaks TB incidence in March, April, and December every year, and the predicted number of TB cases in 2020 was 1 985. The observed and predicted number of TB cases from January 2020 to May 2020 were statistically significant (Z =-2. 023, P0. 05). Conclusion It is necessary to increase the intensity of early warning of TB in March, April, and December every year in Tangshan to prevent the epidemic of TB. At the same time, the coordination of the staff of TB prevention institutions and the emergency system should be strengthened during the epidemic situation of COVID-19, and effectively ensure the registration and medical treatment of TB patients during the epidemic situation. © 2023, Editorial Department of Medical Pest Control. All rights reserved.

Clinical Efficacy of Modified Sanxiaoyin in Treatment of Mild or Moderate COVID-19 Patients：Based on Retrospective Analysis

［］ Objective： To retrospectively analyze the clinical data of 52 patients with coronavirus disease-2019 （COVID-19） and explore the clinical efficacy of modified Sanxiaoyin on mild/moderate COVID-19 patients. Method： The propensity score matching method was used to collect the clinical data of mild or moderate COVID-19 patients enrolled in the designated hospital of the Second Hospital of Jingzhou from December 2019 to May 2020. A total of 26 eligible patients who were treated with modified Sanxiaoyin were included in the observation group，and the 26 patients treated with conventional method were the regarded as the control. The disappearance of clinical symptoms，disappearance time of main symptoms，efficacy on traditional Chinese medicine（TCM）symptoms，hospitalization duration，laboratory test indicators，and CT imaging changes in the two groups were compared. Result： The general data in the two groups were insignificantly different and thus they were comparable. After 7 days of treatment，the disappearance rate of fever，cough， fatigue，dry throat，anorexia，poor mental state，and poor sleep quality in the observation group was higher than that in the control group（P<0.05），and the difference in the disappearance rate of expectoration and chest distress was insignificant. For the cases with the disappearance of symptoms，the main symptoms（fever， cough，fatigue，dry throat，anorexia，chest distress）disappeared earlier in the observation group than in the control group（P<0.01）. After 7 days of treatment，the scores of the TCM symptom scale of both groups decreased（P<0.01），and the decrease of the observation group was larger that of the control group（P<0.01）. All patients in the two groups were cured and discharged. The average hospitalization duration in the observation group［（12.79±2.68）d］was shorter than that in the control group［（15.27±3.11）d］（P<0.01）. The effective rate in the observation group（92.31%，24/26）was higher than that in the control group（76.92%，20/26）. After 7 days of treatment，the lymphocyte（LYM）count increased（P<0.05），and white blood cell（WBC）count and neutrophil（NEUT）count decreased insignificantly in the two groups. Moreover，levels of C-reactive protein （CRP），erythrocyte sedimentation rate（ESR），and procalcitonin（PCT）reduced in the two groups after treatment（P<0.01）and the reduction in the observation group was larger than that in the control group （P<0.01）. Through 7 days of treatment，the total effective rate on pulmonary shadow in the observation group （90.00%，18/20）was higher than that in the control group（77.27%，17/22）（P>0.05）and the improvement of lung shadow in the observation group was better than that in the control group（P<0.01）. Conclusion：Modified Sanxiaoyin can significantly alleviate fever，cough，fatigue，anorexia，chest distress，poor sleep quality，and other symptoms of patients with mild or moderate COVID-19，improve biochemical indicators，and promote the recovery of lung function. This paper provides clinical evidence for the application of modified Sanxiaoyin in the treatment of mild or moderate COVID-19. © 2022, China Academy of Chinese Medical Sciences Institute of Chinese Materia Medica. All rights reserved.

[Establishment of index system for population based SARS-CoV-2 nucleic acid screening].

Objective: To establish an index system of population based SARS-CoV-2 nucleic acid screening, and provide reference to determine the screening coverage appropriately. Methods: The literature review and brain storming sessions were used to develop the basic frame and index system of population based SARS-CoV-2 nucleic acid screening. Based on Delphi method and Analytic Hierarchy Process, 21 domestic experts were selected for two rounds of consultation to determine the index system of population based SARS-CoV-2 nucleic acid screening and its weight. Results: The positive indexes of experts in two rounds of consultations were both 100%. The experts' authority coefficients (Cr) were 0.88±0.08 and 0.89±0.07, respectively. And the range of coefficient of variation (CV) were (0.08, 0.24), (0.09, 0.25). The Kendall's W coordination coefficients were 0.34 and 0.22 respectively, which were statistically significant. The index system of population based SARS-CoV-2 nucleic acid screening was established, which had 4 first-level indexes, 11 second-level indexes and 58 third-level indexes. Besides, the weight of each index was determined. Conclusion: The index system of population based SARS-CoV-2 nucleic acid screening has been established, which can provide scientific reference for the health administration to determine the coverage of population based SARS-CoV-2 nucleic acid screening when local COVID-19 epidemic occurs.

[Sensitivity and specificity of nucleic acid testing in close contacts of COVID-19 cases in Guangzhou].

Objective: To analyze the sensitivity and specificity of SARS-CoV-2 nucleic acid testing in 20 348 close contacts of COVID-19 cases in different prevention and control stages in Guangzhou and to provide scientific evidence for optimizing epidemic response strategies. Methods: A total of 20 348 close contacts of COVID-19 cases in Guangzhou were traced between February 21 and September 22,2020. All the close contacts were tested for the nucleic acid of SARS-CoV-2. The sensitivity and specificity of nucleic acid testing and diagnosis in the different prevention and control stages were compared. Results: In 20 348 close contacts, 12 462 were males (61.24%), the median (P25,P75) of age of them was 31.0 years (23.0,43.0), the median number (P25,P75) of nucleic acid testing for them was 2.0 (1.0,3.0), and the median (P25,P75) of their quarantine days was 12.0 (8.0,13.0) days, respectively. A total of 256 COVID-19 cases were confirmed in the close contacts after seven nucleic acid tests. In the 1st, 2nd, 3rd and 7th nucleic acid testing, the sensitivity and specificity were 69.14% and 99.99% (177 cases confirmed), 89.84% and 99.99% (230 cases confirmed), 97.27% and 99.99% (249 cases confirmed), and 100.00% and 99.98%, respectively. In the three stages of COVID-19 prevention and control in China: domestic case stage, imported case stage, and imported case associated local epidemic stage, the sensitivity of the 1st nucleic acid testing was 70.68%, 68.00% and 67.35%, and the specificity was 99.98%, 100.00% and 100.00%, respectively. Conclusions: The sensitivity of nucleic acid testing in the close contacts at the different stages were consistent with slight decrease, which might be related to the increased proportion of asymptomatic infections in the late stage of epidemic prevention and control with COVID-19 in Guangzhou. It is suggested to give three nucleic acid tests to improve the sensitivity and reduce false negative risk.